Jiang and colleagues orally administered two presumed TrkB agonists (7,8-DHF and 4′-DMA-7,8-DHF) to N171-82Q mice and showed increased striatal TrkB phosphorylation, significantly improved motor function, increased lifespan, and reduced brain atrophy in treated animals.89 Simmons and colleagues90 demonstrated similar benefits from another TrkB agonist, LM22A-4, in the R6/2 and BACHD models, and additionally showed reduced intranuclear aggregation of mHTT in striatum and cortex. Here, NTRK2 is linked to Brain atrophy.